Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes

Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755

Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease

LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378

Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study

Penno, G., Solini, A., Zoppini, G., Fondelli, C., Trevisan, R., Vedovato, M., Gruden, G., Lamacchia, O., Pontiroli, A. E., Arosio, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125512 · Cited by 43

Relative safety profiles of high dose statin regimens

Barrios, V. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s2048 · Cited by 43

Lipid-lowering therapy: who can benefit

Lewis, S. J. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s23113 · Cited by 44

Nanomedicine in coronary artery disease

Ambesh, P., Campia, U., Obiagwu, C., Bansal, R., Shetty, V., Hollander, G. M., & Shani, J. (2017) · Indian Heart Journal · doi:10.1016/j.ihj.2017.02.007 · Cited by 43

Targeting Inflammation After Myocardial Infarction

Mahtta, D., Sudhakar, D., Koneru, S., Silva, G. V., Alam, M., Virani, S. S., & Jneid, H. M. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01358-2 · Cited by 43

Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids

Semova, I., Levenson, A. E., Krawczyk, J., Bullock, K. H., Gearing, M. E., Ling, A. V., Williams, K., Miao, J., Adamson, S. S., Shin, D., et al. (2022) · Circulation · doi:10.1161/circulationaha.120.045373 · Cited by 43

Lp(a): a New Pathway to Target?

Nurmohamed, N. S., Kraaijenhof, J. M., & Stroes, E. S. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01060-4 · Cited by 43

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial

for the BIP Study Group, Arbel, Y., Klempfner, R., Erez, A., Goldenberg, I., Benzekry, S., Shlomo, N., Fisman, E. Z., & Tenenbaum, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0332-6 · Cited by 40

Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events

Rubenfire, M., Brook, R. D., & Rosenson, R. S. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.03.024 · Cited by 40

High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial

Nishikido, T., Oyama, J., Keida, T., Ohira, H., & Node, K. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.05.017 · Cited by 40

Dose-related Effect of Statins in Venous Thrombosis Risk Reduction

Khemasuwan, D., Chae, Y. K., Gupta, S., Carpio, A., Yun, J. H., Neagu, Ş. I., Bianchi, A. L., Valsecchi, M. E., & Mora, J. I. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.04.019 · Cited by 40

Comparative effects of statins on major cerebrovascular events: a multiple-treatments meta-analysis of placebo-controlled and active-comparator trials

Naci, H., Brugts, J. J., Fleurence, R., & Ades, A. E. (2013) · QJM · doi:10.1093/qjmed/hct041 · Cited by 38

Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention

Laufs, U., Descamps, O. S., Catapano, A. L., & Packard, C. J. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu228 · Cited by 38

Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial

Marchioli, R., Levantesi, G., Silletta, M. G., Barlera, S., Bernardinangeli, M., Carbonieri, E., Cosmi, F., Franzosi, M. G., Latini, R., Lucci, D., et al. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.70 · Cited by 40

Secondary prevention after coronary artery bypass graft surgery

Kulik, A. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000331 · Cited by 40

Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation

Ara, R., Pandor, A., Stevens, J., Rees, A., & Rafia, R. (2009) · Health Technology Assessment · doi:10.3310/hta13340 · Cited by 40

Dalcetrapib: a review of Phase II data

Robinson, J. G. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.488219 · Cited by 38

Potentially inappropriate medications and adverse drug effects in elders in the ED

Nixdorff, N., Hustey, F. M., Brady, A. K., Vaji, K., Leonard, M. C., & Messinger‐Rapport, B. J. (2008) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2007.12.007 · Cited by 39

How a Meta‐Analysis Works

Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009) · doi:10.1002/9780470743386.ch1 · Cited by 39

Optimal Management of Combined Dyslipidemia: What Have We Behind Statins Monotherapy?

Tenenbaum, A., Fisman, E. Z., Motro, M., & Adler, Y. (2008) · Advances in cardiology · doi:10.1159/000115192 · Cited by 38

Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study

Fuentes, F. J., Alcala-Diaz, J. F., Watts, G. F., Rodrigo Alonso, K., Muñiz-Grijalvo, O., Díaz-Díaz, J. L., Mata, N., Muñoz-Torrero, J. F. S., Brea, Á., Galiana, J., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.107 · Cited by 38

Effect of Pitavastatin Compared with Atorvastatin andRosuvastatin on New-Onset Diabetes Mellitus in PatientsWith Acute Myocardial Infarction

Choi, J. Y., Choi, C. U., Hwang, S.-Y., Choi, B. G., Jang, W. Y., Kim, D. Y., Kim, W., Park, E. J., Lee, S., Na, J. O., et al. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.06.017 · Cited by 37

Statin use and mortality in atrial fibrillation: A systematic review and meta-analysis of 100,287 patients

Pastori, D., Baratta, F., Rocco, A. D., Farcomeni, A., Ben, M. D., Angelico, F., Violi, F., Pignatelli, P., & Lip, G. Y. H. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105418 · Cited by 37

Pathogenesis and Management of the Diabetogenic Effect of Statins: a Role for Adiponectin and Coenzyme Q10?

Chan, D. C., Pang, J., & Watts, G. F. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0472-7 · Cited by 38

Does Combination Therapy with Statins and Fibrates Prevent Cardiovascular Disease in Diabetic Patients with Atherogenic Mixed Dyslipidemia?

Agouridis, A. P., Rizos, C. V., Elisaf, M., & Filippatos, T. D. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.171 · Cited by 36

Risk of mortality and recurrent cardiovascular events in patients with acute coronary syndromes on high intensity statin treatment

Rockberg, J., Jørgensen, L., Taylor, B., Sobocki, P., & Johansson, G. (2017) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2017.03.001 · Cited by 35

Cardiovascular Benefit of Magnitude of Low-Density Lipoprotein Cholesterol Reduction

Rahilly‐Tierney, C. R., Lawler, E. V., Scranton, R. E., & Gaziano, J. M. (2009) · Circulation · doi:10.1161/circulationaha.108.846931 · Cited by 35

State of the Art: Evaluation and Medical Management of Nonobstructive Coronary Artery Disease in Patients With Chest Pain: A Scientific Statement From the American Heart Association

Slipczuk, L. N., Blankstein, R., Bucciarelli‐Ducci, C., Braun, L. T., Phillips, L. M., Piña, P., Shaw, L. J., Tamis‐Holland, J. E., Williamson, E. E., & Virani, S. S. (2025) · Circulation · doi:10.1161/cir.0000000000001394 · Cited by 38

Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: Results from the Treating to New Targets (TNT) Trial

Mark, D. B., Knight, J. D., Cowper, P. A., Davidson-Ray, L. D., & Anstrom, K. J. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.05.032 · Cited by 34

Primary and Secondary Prevention of Coronary Heart Disease

Gaziano, J. M., Ridker, P. M., & Libby, P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00049-4 · Cited by 34

Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009–2017

Thalmann, I., Preiss, D., Schlackow, I., Gray, A. M., & Mihaylova, B. (2022) · Heart · doi:10.1136/heartjnl-2022-321452 · Cited by 36

Residual risks and evolving atherosclerotic plaques

Noothi, S. K., Ahmed, M. R., & Agrawal, D. K. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04689-0 · Cited by 37

Statins in Acute Coronary Syndromes

Morrissey, R. P., Diamond, G. A., & Kaul, S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.093 · Cited by 35

Dyslipidemia: Management Using Optimal Lipid-Lowering Therapy

Ito, M. K. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r127 · Cited by 34

Lipid-lowering therapy and coronary artery bypass graft surgery

Kulik, A., & Ruel, M. (2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32834b9fb1 · Cited by 33

Prevalence and types of persistent dyslipidemia in patients treated with statins

Reiner, Ž., & Tedeschi-Reiner, E. (2013) · Croatian Medical Journal · doi:10.3325/cmj.2013.54.339 · Cited by 33

Accounting for Clinical Action Reduces Estimates of Gender Disparities in Lipid Management for Diabetic Veterans

Vimalananda, V. G., Miller, D. R., Hofer, T. P., Holleman, R. G., Klamerus, M. L., & Kerr, E. A. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2340-5 · Cited by 34

Models for Describing Relations Among the Various Statin Drugs, Low-Density Lipoprotein Cholesterol Lowering, Pleiotropic Effects, and Cardiovascular Risk††Conflicts of interest: In the past 2 years, Dr. Robinson has received grants from Abbott Laboratories, Abbott Park, Illinois, Astra-Zeneca, Wilmington, Delaware, Bristol-Myers Squibb, Princeton, New Jersey, GlaxoSmithKline, Pittsburgh, Pennsylvania, Hoffman La Roche, Basel, Switzerland, Merck & Company, West Point, Pennsylvania, Pfizer, New York, New York, Procter & Gamble, Cinncinnati, Ohio, Sankyo, Parsippany, New Jersey, Schering-Plough, Kenilworth, New Jersey, and Takeda Pharmaceuticals, Lincolnshire, Illinois and honoraria for education programs from Merck & Company, and has been a consultant and advisory board member for Merck Schering Plough.

Robinson, J. G. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.11.060 · Cited by 33

Statin Treatment Is Associated with Reduction in Serum Levels of Receptor Activator of NF-κB Ligand and Neutrophil Activation in Patients with Severe Carotid Stenosis

Lenglet, S., Quercioli, A., Fabre, M., Galan, K., Pelli, G., Nencioni, A., Bauer, I., Pende, A., Python, M., Bertolotto, M. B., et al. (2014) · Mediators of Inflammation · doi:10.1155/2014/720987 · Cited by 32

The Effect of Simvastatin on Glucose Homeostasis in Streptozotocin Induced Type 2 Diabetic Rats

Wang, L., Duan, G., Lu, Y., Pang, S., Huang, X., Jiang, Q., & Dang, N. (2013) · Journal of Diabetes Research · doi:10.1155/2013/274986 · Cited by 32

Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study

Ohno, Y., Miyoshi, T., Noda, Y., Oe, H., Toh, N., Nakamura, K., Kohno, K., Morita, H., & Ito, H. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-71 · Cited by 31

Class effects of statins in elderly patients with congestive heart failure: A population-based analysis

Rinfret, S., Behlouli, H., Eisenberg, M. J., Humphries, K. H., Tu, J. V., & Pilote, L. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.09.004 · Cited by 31

The Hong Kong Medical Diary

Mok, T. (2010) · The HKU Scholars Hub (University of Hong Kong) · Cited by 31

Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes

Colivicchi, F., Marco Tubaro, U., & Santini, M. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.07.006 · Cited by 30

Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years

Constance, C. M., Ben‐Yehuda, O., WENGER, N. K., Zieve, F. J., Lin, J., Hanson, M. E., Lowe, R. S., & Tershakovec, A. M. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-13 · Cited by 30

Stable Ischemic Heart Disease

Padala, S. K., Sidhu, M. S., & Boden, W. E. (2016) · Springer eBooks · doi:10.1007/978-3-642-37393-0_70-2 · Cited by 30

Activation of microRNA-378a-3p biogenesis promotes hepatic secretion of VLDL and hyperlipidemia by modulating ApoB100-Sortilin1 axis

Zhang, T., Shi, H., Liu, N., Tian, J., Zhao, X., Steer, C. J., Han, Q., & Song, G. (2020) · Theranostics · doi:10.7150/thno.39578 · Cited by 31

Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly

LUCCHI, T. (2022) · Minerva Medica · doi:10.23736/s0026-4806.21.07347-x · Cited by 33

Pharmacotherapy of Diabetes: New Developments

Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 30

Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat

Soran, H., Adam, S., & Durrington, P. N. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316667785 · Cited by 29

Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?

von Eckardstein, A. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.6 · Cited by 30

Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

Frishman, W. H. (2007) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70201-3 · Cited by 29

Stable Ischemic Heart Disease

Morrow, D. A., & Boden, W. E. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00057-3 · Cited by 28

HDL metabolism in context: looking on the bright side

Watts, G. F., Barrett, P. H. R., & Chan, D. C. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328306596d · Cited by 30

Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus

Kajinami, K., & Yasusyuki, K. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s13492 · Cited by 28

Prevention of cardiovascular disease guided by total risk estimations − challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy

Zannad, F. M., Dallongeville, J., MacFadyen, R. J., Ruilope, L. M., Wilhelmsen, L., Backer, G. D., Graham, I. M., Lorenz, M., Mancia, G., Morrow, D. A., et al. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826711424873 · Cited by 28

High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients

Yu, S., Jin, J., Chen, Z., & Luo, X. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01369-6 · Cited by 28

The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Hyperlipidemia

Farnier, M. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11590330-000000000-00000 · Cited by 29

Non-ST Elevation Acute Coronary Syndromes: A Comprehensive Review

Bob‐Manuel, T., Ifedili, I., Reed, G. L., Ibebuogu, U. N., & Khouzam, R. N. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.04.006 · Cited by 33

Simvastatin: present and future perspectives

Robinson, J. G. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.13.2159 · Cited by 32

Alternative LDL Cholesterol–Lowering Strategy vs High-Intensity Statins in Atherosclerotic Cardiovascular Disease

Lee, Y., Hong, B., Yun, K. H., Kang, W. C., Hong, S. J., Lee, S., Lee, S., Hong, S., Ahn, C., Kim, J., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.3911 · Cited by 27

A controlled trial of dissemination and implementation of a cardiovascular risk reduction strategy in small primary care practices

Cykert, S., Keyserling, T. C., Pignone, M. P., DeWalt, D. A., Weiner, B. J., Trogdon, J. G., Wroth, T. H., Halladay, J. R., Mackey, M., Fine, J. P., et al. (2020) · Health Services Research · doi:10.1111/1475-6773.13571 · Cited by 27

Independent and Combined Effects of Aerobic Exercise and Pharmacological Strategies on Serum Triglyceride Concentrations: A Qualitative Review

Plaisance, E. P., Grandjean, P. W., & Mahurin, A. J. (2009) · The Physician and Sportsmedicine · doi:10.3810/psm.2009.04.1678 · Cited by 27

The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy

Wiviott, S. D., & Cannon, C. P. (2006) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328010872d · Cited by 27

The efficacy and safety of high-dose statins in acute phase of ischemic stroke and transient ischemic attack: a systematic review

Fang, J., Wang, E.-Q., Wang, W., Liu, Y., & Cheng, G. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1650-8 · Cited by 27

Statins in the spectrum of neurologic disease

Orr, J. D. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0003-5 · Cited by 27

Effects of Aggressive Statin Therapy on Patients With Coronary Saphenous Vein Bypass Grafts: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials

Kang, S., Liu, Y., & Liu, X. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.06.006 · Cited by 26

Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis

Zhong, P., Wu, D., Ye, X., Wu, Y., Li, T., Tong, S., & Liu, X. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s135785 · Cited by 27

Clinical Significance of Intensive Lipid-Lowering Therapy Using Statins in Patients With Coronary Artery Disease

Miyauchi, K., & Daida, H. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0565 · Cited by 26

Geographic Variation in Statin Use for Complex Acute Myocardial Infarction Patients

Brooks, J. M., Cook, E. A., Chapman, C. G., Kulchaitanaroaj, P., Chrischilles, E. A., Welch, S., & Robinson, J. G. (2014) · Medical Care · doi:10.1097/mlr.0b013e3182a7fc3d · Cited by 26

Clinical review: Impact of statin substitution policies on patient outcomes

Atar, D., Carmena, R., Clemmensen, P. M., Laflamme, A. K., Waßmann, S., Lansberg, P. J., & Hobbs, R. F. (2009) · Annals of Medicine · doi:10.1080/07853890902729786 · Cited by 26

The Science of Ischemic Stroke: Pathophysiology & Pharmacological Treatment

Kanyal, N. (2015) · International journal of pharma research and review · Cited by 26

Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?

Bays, H. E., Conard, S. E., Leiter, L. A., Bird, S. R., Jensen, E. H., Hanson, M. E., Shah, A. K., & Tershakovec, A. M. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-136 · Cited by 25

Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events

Sakuma, M., Iimuro, S., Shinozaki, T., Kimura, T., Nakagawa, Y., Ozaki, Y., Iwata, H., Miyauchi, K., Daida, H., Suwa, S., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02633-5 · Cited by 25

Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction

Makam, R. C. P., Erskine, N. A. K., McManus, D. D., Lessard, D., Gore, J. M., Yarzebski, J., & Goldberg, R. J. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.08.065 · Cited by 25

The Effect of July Admission in the Process of Care of Patients with Acute Cardiovascular Conditions

Garcia, S. A., Canoniero, M. J., & Young, L. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e3181a2f8ca · Cited by 25

Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care

Pepine, C. J. (2010) · Annals of Medicine · doi:10.3109/07853890903260898 · Cited by 25

Randomised comparison of titanium-nitride-oxide coated stents with bare metal stents: five year follow-up of the TiNOX trial

Moschovitis, A., Simon, R., Seidenstücker, A., Klauß, V., Baylacher, M., Lüscher, T. F., Moccetti, T., Windecker, S., Meier, B., & Hess, O. M. (2010) · EuroIntervention · doi:10.4244/eijv6i1a10 · Cited by 26

Efficacy and Safety of Ezetimibe and Ezetimibe Plus Statin Therapy in Patients Aged Under 65, 65–74 and 75 Years and Older

Robinson, J. G., Davidson, M. H., Shah, A. K., Lin, J., Neff, D., DeLucca, P. T., Tomassini, J. E., Veltri, E. P., & Tershakovec, A. M. (2007) · Aging Health · doi:10.2217/1745509x.3.6.691 · Cited by 25

Influence of food components on lipid metabolism: scenarios and perspective on the control and prevention of dyslipidemias

Frota, K. D. M. G., Matias, A. C. G., & Arêas, J. A. G. (2010) · Food Science and Technology · doi:10.1590/s0101-20612010000500002 · Cited by 25

Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease

O'Brien, E. C., Wu, J., Schulte, P. J., Christian, A., Laskey, W. K., Bhatt, D. L., Peterson, E. D., Hernandez, A. F., & Fonarow, G. C. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.11.014 · Cited by 24

Systematic review of clinical guidelines for lipid lowering in the secondary prevention of cardiovascular disease events

Brown, R., Welsh, P. I., & Logue, J. (2020) · Open Heart · doi:10.1136/openhrt-2020-001396 · Cited by 24

The Unhidden Cost of Noncompliance

Mahoney, J. J., Ansell, B. J., Fleming, W. K., & Butterworth, S. W. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s6-b.1 · Cited by 24

Frequency of High-Risk Patients Not Receiving High-Potency Statin (from a Large Managed Care Database)

Rodríguez, F., Olufade, T. O., Heithoff, K. A., Friedman, H. S., Navaratnam, P., & Foody, J. M. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.10.021 · Cited by 23

High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n‐3 Fatty Acids in Mixed Dyslipidemia

Agouridis, A. P., Tsimihodimos, V., Filippatos, T. D., Tselepis, A. D., & Elisaf, M. (2011) · Lipids · doi:10.1007/s11745-011-3538-0 · Cited by 23

Statins in acute coronary syndrome: very early initiation and benefits

Angeli, F., Reboldi, G., Mazzotta, G., Garofoli, M., Cerasa, M. F., & Verdecchia, P. (2012) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944712452463 · Cited by 23

Investigating cholesterol metabolism and ageing using a systems biology approach

Morgan, A. E., Mooney, K. M., Wilkinson, S. J., Pickles, N. A., & Auley, M. T. M. (2016) · Proceedings of The Nutrition Society · doi:10.1017/s0029665116002822 · Cited by 23

Emerging Fixed-Dose Combination Treatments for Hyperlipidemia

Pappa, E. T., Rizos, C. V., Filippatos, T. D., & Elisaf, M. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248419838506 · Cited by 23

Dyslipidemia in Chronic Kidney Disease: Are Statins Still Indicated in Reduction Cardiovascular Risk in Patients on Dialysis Treatment?

Scarpioni, R., Ricardi, M., Melfa, L., & Cristinelli, L. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00182.x · Cited by 24

Incidence of Musculoskeletal and Neoplastic Diseases in Patients on Statin Therapy: Results of a Retrospective Cohort Analysis

Mansi, I. A., Mortensen, E. M., Pugh, M. J., Wegner, M., & Frei, C. R. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31825b8edf · Cited by 22

Statins in cardiometabolic disease: what makes pitavastatin different?

Ginsberg, H. N. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-s1-s1 · Cited by 25

Lipid management in ACS: Should we go lower faster?

Gencer, B., & Mach, F. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.871 · Cited by 21

Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis

Jaam, M. J., Al-Naimi, H., Haddad, M. M., Abushanab, D., & Al‐Badriyeh, D. (2023) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2022-0163 · Cited by 24

Low‐Density Lipoprotein Levels in Patients With Acute Heart Failure

Kahn, M. R., Kosmas, C. E., Wagman, G., Serrao, G. W., Fallahi, A., Grady, K. M., & Vittorio, T. J. (2012) · Congestive Heart Failure · doi:10.1111/chf.12006 · Cited by 21

Low-density lipoprotein cholesterol target achievement in patients at high risk for coronary heart disease

Kitkungvan, D., Fillipon, N. M. L., Dani, S. S., & Downey, B. C. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.06.003 · Cited by 21

Consensus statement on the management of dyslipidaemias in adults

Béliard, S., Bonnet, F., Bouhanick, B., Bruckert, É., Cariou, B., Charrière, S., Durlach, V., Moulin, P., Valéro, R., & Vergès, B. L. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.07.033 · Cited by 21

On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)

Blazing, M. A., Giugliano, R. P., de Lemos, J. A., Cannon, C. P., Tonkin, A. M., Ballantyne, C. M., Lewis, B. S., Musliner, T. A., Tershakovec, A. M., Lokhnygina, Y. V., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.09.004 · Cited by 21

Patient-related characteristics associated with non-persistence with statin therapy in elderly patients following an ischemic stroke

Wawruch, M., Zatko, D., Wimmer, G., Luha, J., Hricak, V., Murín, J., Kukumberg, P., Tesař, T., Hloska, A., & Shah, R. R. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4148 · Cited by 21

Effects of Statin Intensity on Clinical Outcome in Acute Myocardial Infarction Patients

Hwang, D., Kim, H. K., Lee, J. M., Choi, K. H., Kim, J., Rhee, T., Park, J., Park, T. K., Yang, J. H., Song, Y. B., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-1221 · Cited by 21

The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy

Candrilli, S. D., Manjunath, R., Davis, K. L., & Gidal, B. E. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.07.021 · Cited by 21

Review: high dose statins reduce risk of non-fatal cardiovascular events more than standard dose statins

Newby, L. K. (2007) · BMJ Evidence-Based Medicine · doi:10.1136/ebm.12.2.42

The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials

Josan, K., Majumdar, S. R., & McAlister, F. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.070675 · Cited by 197

Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients

Mills, E. J., O’Regan, C., Eyawo, O., Wu, P., Mills, F. P., Berwanger, O., & Briel, M. (2017) · reroDoc Digital Library

Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins

Chan, D. K. Y., O’Rourke, F., Shen, Q. X., Mak, J. C. S., & Hung, W. T. (2010) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2010.01450.x · Cited by 26

Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients

Ribeiro, R. A., Ziegelmann, P. K., Duncan, B. B., Stella, S. F., Vieira, J. L. D. C., Restelatto, L. M. F., Moriguchi, E. H., & Polanczyk, C. A. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.10.128 · Cited by 34